Health AI Central
Peer-Reviewed Publication
Immunity2026June 11, 2026Journal Article

Immunoediting restricts clonal neoantigens in primary, treatment-naive human tumors.

Elizabeth S Borden1, David Castellano2, Emily A Kantzos3, Alysia Hughes4, Zachary Leibovit-Reiben4, Alyssa Stockard4, Anirudh Choudhary5, Tao Ma4, Xing Li4, Aaron R Mangold4, Ryan N Gutenkunst2, Bonnie J LaFleur6, Kenneth H Buetow7, Melissa A Wilson7, Karen Taraszka Hastings8
1Department of Dermatology, College of Medicine-Phoenix, University of Arizona, Phoenix, AZ 85004, USA; Phoenix Veterans Affairs Health Care System, Phoenix, AZ 85012, USA.
2Department of Molecular and Cellular Biology, University of Arizona, Tucson, AZ 85721, USA.
3Department of Dermatology, College of Medicine-Phoenix, University of Arizona, Phoenix, AZ 85004, USA.
4Department of Dermatology, Mayo Clinic Health System, Scottsdale, AZ 85259, USA.
5Department of Electrical and Computer Engineering, University of Illinois Urbana-Champaign, Champaign, IL 61801, USA.
6BIO5 Institute, University of Arizona, Tucson, AZ 85719, USA; R. Ken Coit College of Pharmacy, University of Arizona, Tucson, AZ 85724, USA.
7School of Life Sciences, Arizona State University, Tempe, AZ 85281, USA; Center for Evolution and Medicine, Arizona State University, Tempe, AZ 85281, USA.
8Department of Dermatology, College of Medicine-Phoenix, University of Arizona, Phoenix, AZ 85004, USA; Phoenix Veterans Affairs Health Care System, Phoenix, AZ 85012, USA; University of Arizona Cancer Center, University of Arizona, Tucson, AZ 85719, USA. Electronic address: khasting@arizona.edu.
PubMed DOI

Abstract

T cell targeting of cancer cells alters the tumor antigen landscape in preclinical models. Here, we examined the impact of immunoediting on the antigenic landscape of primary, treatment-naive human tumors. Cutaneous squamous cell carcinoma tumors from immunocompetent and immunosuppressed patients revealed consistent tumor mutational signatures; however, high-immune-infiltrate tumors from immunocom…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free AccountSign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.